Economic evaluation of Zika Contraception Access Network in Puerto Rico during the 2016-17 Zika virus outbreak.


Journal

Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361

Informations de publication

Date de publication:
03 2022
Historique:
received: 05 02 2021
revised: 04 10 2021
accepted: 23 10 2021
pubmed: 9 11 2021
medline: 23 4 2022
entrez: 8 11 2021
Statut: ppublish

Résumé

During the 2016-2017 Zika virus (ZIKV) outbreak, the prevention of unintended pregnancies was identified as a primary strategy to prevent birth defects. This study estimated the cost-effectiveness of the Zika Contraception Access Network (Z-CAN), an emergency response intervention that provided women in Puerto Rico with access to the full range of reversible contraception at no cost and compared results with a preimplementation hypothetical cost-effectiveness analysis (CEA). We evaluated costs and outcomes of Z-CAN from a health sector perspective compared to no intervention using a decision tree model. Number of people served, contraception methods mix, and costs under Z-CAN were from actual program data and other input parameters were from the literature. Health outcome measures included the number of Zika-associated microcephaly (ZAM) cases and unintended pregnancies. The economic benefits of the Z-CAN intervention were ZIKV-associated direct costs avoided, including lifetime medical and supportive costs associated with ZAM cases, costs of monitoring ZIKV-exposed pregnancies and infants born from Zika-virus infected mothers, and the costs of unintended pregnancies prevented during the outbreak as a result of increased contraception use through the Z-CAN intervention. The Z-CAN intervention cost a total of $26.1 million, including costs for the full range of reversible contraceptive methods, contraception related services, and programmatic activities. The program is estimated to have prevented 85% of cases of estimated ZAM cases and unintended pregnancies in the absence of Z-CAN. The intervention cost was projected to have been more than offset by $79.9 million in ZIKV-associated costs avoided, 96% of which were lifetime ZAM-associated costs, as well as $137.0 million from avoided unintended pregnancies, with total net savings in one year of $216.9 million. The results were consistent with the previous CEA study. Z-CAN was likely cost-saving in the context of a public health emergency response setting.

Identifiants

pubmed: 34748752
pii: S0010-7824(21)00440-6
doi: 10.1016/j.contraception.2021.10.009
pmc: PMC8897811
mid: NIHMS1781339
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

68-73

Subventions

Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Références

Int Perspect Sex Reprod Health. 2011 Jun;37(2):84-94
pubmed: 21757423
J Public Health Manag Pract. 2022 Mar-Apr 01;28(2):E506-E517
pubmed: 33729201
Obstet Gynecol. 2012 Dec;120(6):1291-7
pubmed: 23168752
Emerg Infect Dis. 2018 Dec;24(12):2251-2261
pubmed: 30457546
Eur J Contracept Reprod Health Care. 2008 Sep;13(3):219-21
pubmed: 18821460
MMWR Morb Mortal Wkly Rep. 2017 Jun 16;66(23):615-621
pubmed: 28617773
MMWR Morb Mortal Wkly Rep. 2020 Jan 24;69(3):67-71
pubmed: 31971935
Perspect Sex Reprod Health. 2017 Mar;49(1):7-16
pubmed: 28245088
Obstet Gynecol. 2020 May;135(5):1095-1103
pubmed: 32282596
AIP Conf Proc. 2010 Jan 5;1204:17-21
pubmed: 20733932
Birth Defects Res. 2019 Aug 1;111(13):938-940
pubmed: 31264801
Am J Public Health. 2018 Sep;108(S3):S227-S230
pubmed: 30192658
PLoS Negl Trop Dis. 2016 Oct 20;10(10):e0005075
pubmed: 27764085
Am J Prev Med. 2008 Dec;35(6):572-7
pubmed: 18845415
Contraception. 2020 Nov;102(5):356-360
pubmed: 32858052
Contraception. 2015 Jan;91(1):49-56
pubmed: 25282161
Am J Public Health. 1995 Apr;85(4):494-503
pubmed: 7702112
J Infect Dis. 2018 May 5;217(11):1678-1689
pubmed: 29216376
MMWR Morb Mortal Wkly Rep. 2016 Apr 01;65(12):311-4
pubmed: 27031817
MMWR Morb Mortal Wkly Rep. 2017 Apr 07;66(13):366-373
pubmed: 28384133
J Womens Health (Larchmt). 2020 Nov;29(11):1372-1380
pubmed: 33196331
Health Aff (Millwood). 2017 Dec;36(12):2160-2164
pubmed: 29200346
Contraception. 2020 Jun;101(6):405-411
pubmed: 32194040
Emerg Infect Dis. 2017 Jan;23(1):74-82
pubmed: 27805547
Stud Fam Plann. 2010 Dec;41(4):241-50
pubmed: 21465725
Contraception. 2009 Jan;79(1):5-14
pubmed: 19041435
Lancet Public Health. 2018 Feb;3(2):e91-e99
pubmed: 29371100
Am J Obstet Gynecol. 2004 Mar;190(3):721-9
pubmed: 15042005
Epidemiol Health. 2014 Oct 30;36:e2014025
pubmed: 25358466

Auteurs

Rui Li (R)

Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: rli@hrsa.gov.

Sascha R Ellington (SR)

Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Romeo R Galang (RR)

Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Scott D Grosse (SD)

National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Zipatly Mendoza (Z)

National Foundation for the Centers for Disease Control and Prevention, Atlanta, GA, USA.

Stacey Hurst (S)

Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Yari Vale (Y)

University of Puerto Rico, Department of Gynecology and Obstetrics, San Juan, Puerto Rico.

Eva Lathrop (E)

Department of Obstetrics and Gynecology, Emory University School of Medicine, Atlanta, GA, USA.

Lisa Romero (L)

Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH